EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSSLUG00000018152
Gene Symbol: CACNA1B
1 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSSLUG00000011983
Gene Symbol: CACNA1D
1 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSSLUG00000011517
Gene Symbol: CACNA1E
1 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSSLUG00000001187
Gene Symbol: CACNA1E
1 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSSLUG00000007150
Gene Symbol: CACNA1G
1 Cross references
196 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSSLUG00000021060
Gene Symbol: CNR1
1 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSSLUG00000017528
Gene Symbol: CNR1
3 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSSLUG00000014267
Gene Symbol: CNR2
1 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSSLUG00000017761
Gene Symbol: CA12
1 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSSLUG00000005873
Gene Symbol: CA14
3 Cross references
210 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSSLUG00000006088
Gene Symbol: LOC116058183
3 Cross references
212 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSSLUG00000007204
Gene Symbol: LOC116048471
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).